Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512769 | 0.82 | HSD11B1 (0.56) | MMP1CA1CA2CA9TSHR | |
| SCHEMBL3068587 | 0.81 | SCN3A (0.57) | SCN3AMMP1NPC1KMT2A | |
| SCHEMBL3051021 | 0.81 | SCN3A (0.54) | SCN3AMMP1NPC1KMT2A | |
| SCHEMBL2352042 | 0.81 | NPC1 (0.65) | CA1CA2CA9CA5ATSHR | |
| SCHEMBL16273102 | 0.81 | KMT2A (0.60) | MMP1CA9TSHRKCNJ1KCNH2 | |
| SCHEMBL30396356 | 0.80 | SCN3A (0.53) | SCN3AMMP1CA1CA2HSD11B1 | |
| SCHEMBL439543 | 0.78 | CA1 (0.60) | CA1CA2CA9CA5AHSD11B1 | |
| SCHEMBL27947182 | 0.76 | CA1 (0.61) | MMP1CA1CA2CA9CA5A | |
| SCHEMBL19126866 | 0.76 | CA2 (0.59) | MMP1CA1CA2CA9CA5A | |
| SCHEMBL31540565 | 0.75 | TSHR (0.56) | CA1CA2CA9CA5ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357685-A1 | Sodium Channel Inhibitors | ICAGEN INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357685-A1 | Sodium Channel Inhibitors | ICAGEN INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357685-A1 | Sodium Channel Inhibitors | ICAGEN INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-8853250-B2 | Sodium channel inhibitors | ICAGEN, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853250-B2 | Sodium channel inhibitors | ICAGEN, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853250-B2 | Sodium channel inhibitors | ICAGEN, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20100267782-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267782-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267782-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2175728-A1 | SODIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009012241-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012241-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357685-A1 | Sodium Channel Inhibitors | TRPV1, SCN1A, SCN2A | SCN3A 8/4885MMP1 2075/4885CA1 1231/4885 |
| US-20100267782-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | SCN3A 8/4885MMP1 2075/4885CA1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.